GRN and multiple sclerosis: Although downregulating TREM2 expression or reducing CSF sTREM2 levels could be a therapeutic target for individuals with FTD secondary to GRN mutations, animal models of multiple sclerosis deteriorated with TREM2 inhibition [42].